06:31:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-28 Bokslutskommuniké 2024
2024-11-15 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-27 Ordinarie utdelning INIT 0.00 SEK
2024-05-24 Årsstämma 2024
2024-05-10 Kvartalsrapport 2024-Q1
2024-02-23 Bokslutskommuniké 2023
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-29 Ordinarie utdelning INIT 0.00 SEK
2023-05-26 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-11-04 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-23 Ordinarie utdelning INIT 0.00 SEK
2022-05-20 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-18 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-31 Ordinarie utdelning INIT 0.00 SEK
2021-05-28 Årsstämma 2021
2021-05-25 Kvartalsrapport 2021-Q1
2021-05-11 Extra Bolagsstämma 2021
2021-02-19 Bokslutskommuniké 2020
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-25 Ordinarie utdelning INIT 0.00 SEK
2020-05-22 Årsstämma 2020
2020-05-22 Kvartalsrapport 2020-Q1
2020-02-21 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning INIT 0.00 SEK
2019-05-23 Kvartalsrapport 2019-Q1
2019-05-23 Årsstämma 2019
2019-02-22 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-28 Ordinarie utdelning INIT 0.00 SEK
2018-05-25 Årsstämma 2018
2018-05-25 Kvartalsrapport 2018-Q1
2018-03-01 Extra Bolagsstämma 2017
2018-02-21 Bokslutskommuniké 2017
2017-11-24 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-26 Kvartalsrapport 2017-Q1
2017-05-17 Ordinarie utdelning INIT 0.00 SEK
2017-05-16 Årsstämma 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Initiator Pharma är verksamma inom bioteknik. Idag innehas störst affärsinriktning mot utveckling av läkemedelskandidater som används vid behandling av erektil dysfunktion hos män. Bolaget har för tillfället läkemedel under testning i klinisk fas för patienter som inte svarar på PDE5i läkemedel. Initiator Pharma kom till via en spin-off från Saniona och har idag sitt huvudkontor i Åbyhøj.
2022-10-04 08:50:00

The AGM held on May 24, 2022 approved two long-term incentive programs (“LTI2022”), one for Management and leading employees and one for board members.

LTI2022 for Management and leading employees:
Under the program for Management and leading employees the board is authorized to allow participants in the program to acquire up to 110.000 ordinary shares in the market at market price (“Investment Shares”) until September 30, 2022, with each Investment Share carrying the right to subscribe for 1 new share at par value at the next AGM providing that the individual owning the Investment Share is still with the company at the time (“Matching Share”). Each Investment Share is also entitled to subscribe for between 0 and 5 new shares at par value during 30 trading days after December 31, 2024, depending on the development of Initiator’s share price in the period between May 24 2022 and December 31 2024. The maximum potential dilution under the approved program is 660,000 shares, representing approx. 1.2% of currently issued number of shares.

The board has decided to allocate a total of maximum 110.000 shares that can be purchased under this program, representing a potential dilution of 660.000 shares and approx. 1.20% of currently issued number of shares. By the end of the allowable investment period the maximum number of shares has been purchased in the market.

LTI2022 for Board members:
Under the program for Board members the board is authorised to allow participants in the program to acquire up to 31.000 ordinary shares in the market at market price (“Investment Shares”) until September 30, 2022, with each Investment Share carrying the right to acquire 1 new share from the company at par value at the next AGM providing that the individual owning the Investment Share is still with the company at the time (“Matching Share”). Each Investment Share is also entitled to acquire between 0 and 5 new shares from the company at par value during 30 trading days after December 31, 2024, depending on the development of Initiator’s share price in the period between May 24 2022 and December 31 2024. The maximum potential dilution under the approved program is 186,000 shares, representing approx. 0.3% of currently issued number of shares.

The board has decided to allocate a total of maximum 31.000 shares that can be purchased under this program, representing a potential dilution of 186.000 shares and approx. 0.3% of currently issued number of shares. By the end of the allowable investment period 19.500 shares has been purchased in the market, representing a potential dilution of 0.2%.

In the table below an overview of shares and warrants held by the board of directors, executive management and key employees is presented. The overview comprises warrants from the incentive programmes for 2020, 2021 and 2022, respectively.

IndividualPositionSharesWarrants


Total
Shares and warrants
Pct
fully diluted



202020212022Total
warrants


Magnus PerssonBoard member256 68660 78850 00015 000125 788382 4740,70%
Henrik MoltkeBoard member127 10626 05235 00042 000103 052230 1580,42%
Peter HolmBoard member-------
Annette ColinBoard member17 000-35 00018 00053 00070 0000,13%
Gunilla EkströmBoard member7 000--42 00042 00049 0000,09%
Total BoD407 79286 840120 000117 000323 840731 6321,35%
Claus OlesenCEO and board member1 072 43882 497300 000210 000592 4971 664 9353,06%
Other mgmt. and leading employees2 891 600264 859330 000450 0001 044 8593 936 4597,25%
Total Mgmt and leading employees3 964 038347 356630 000660 0001 637 3565 601 39410,31%
Total BoD, Mgmt and leading employees4 371 830434 196750 000777 0001 961 1966 333 02611,66%